Vaginal Drug Delivery Systems for HIV Prevention

Overview

Journal AAPS J

Specialty Pharmacology

Date 2009 Feb 6

PMID 19194802

Citations 60

Authors

Lisa Cencia Rohan

Alexandra B Sassi

Affiliations

Soon will be listed here.

Abstract

Microbicides have become a principal focus for HIV prevention strategies. The successful design of drug delivery systems for vaginal microbicide drug candidates brings with it a multitude of challenges. It is imperative that the chemical and physical characteristics of the drug candidate and its mechanism of action be clearly understood and considered to successfully deliver and target drug candidates efficiently. In addition, an understanding of the dynamic nature of the vaginal environment, the tissue and innate barriers present, as well as patient preferences are critical considerations in the design of effective microbicide products. Although the majority of drug candidates clinically evaluated to date have been delivered using conventional semisolid aqueous-based gel dosage forms, drug delivery system design has recently been extended to include advanced delivery systems such as vaginal rings, quick-dissolve films, and tablets. Ultimately, it may be necessary to develop multiple dosage platforms for a single active agent to provide users with options that can be used within the constraints of their social environment, personal choice, and environmental conditions.

Citing Articles

Recent Advances in Studying In Vitro Drug Permeation Across Mucosal Membranes.

Song J, Xu Z, Xie L, Shen J Pharmaceutics. 2025; 17(2).

PMID: 40006623 PMC: 11858820. DOI: 10.3390/pharmaceutics17020256.

Nanomedicine for Maternal and Fetal Health.

Carter D, Better M, Abbasi S, Zulfiqar F, Shapiro R, Ensign L Small. 2023; 20(41):e2303682.

PMID: 37817368 PMC: 11004090. DOI: 10.1002/smll.202303682.

Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies.

Mohammadi-Meyabadi R, Beirampour N, Garros N, Alvarado H, Limon D, Silva-Abreu M Pharmaceutics. 2022; 14(12).

PMID: 36559208 PMC: 9785369. DOI: 10.3390/pharmaceutics14122714.

Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV.

Zondo N, Sobia P, Sivro A, Ngcapu S, Ramsuran V, Archary D Front Genet. 2022; 13:940661.

PMID: 36246609 PMC: 9557974. DOI: 10.3389/fgene.2022.940661.

Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention.

Tong X, Patel S, Li J, Patton D, Xu E, Anderson P Polymers (Basel). 2022; 14(6.

PMID: 35335526 PMC: 8955144. DOI: 10.3390/polym14061196.

References

Garg S, Vermani K, Garg A, Anderson R, Rencher W, Zaneveld L . Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res. 2005; 22(4):584-95. DOI: 10.1007/s11095-005-2490-1. View

Johansson E, Rudin A, Wassen L, Holmgren J . Distribution of lymphocytes and adhesion molecules in human cervix and vagina. Immunology. 1999; 96(2):272-7. PMC: 2326729. DOI: 10.1046/j.1365-2567.1999.00675.x. View

Mauck C, Weiner D, Ballagh S, Creinin M, Archer D, Schwartz J . Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study. Contraception. 2004; 70(1):77-83. PMC: 2861169. DOI: 10.1016/j.contraception.2004.02.016. View

Garg S, Anderson R, Chany 2nd C, Waller D, Diao X, Vermani K . Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception. 2001; 64(1):67-75. DOI: 10.1016/s0010-7824(01)00217-7. View

Rohan L, Ratner D, McCullough K, Hiller S, Gupta P . Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Sex Transm Dis. 2004; 31(3):143-8. DOI: 10.1097/01.olq.0000114655.79109.ed. View

Lard-Whiteford S, Matecka D, ORear J, Yuen I, Litterst C, Reichelderfer P . Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. J Acquir Immune Defic Syndr. 2004; 36(1):541-52. DOI: 10.1097/00126334-200405010-00001. View

Yotsuyanagi T, Molokhia A, Hwang S, Ho N, Flynn G, Higuchi W . Systems approach to vaginal delivery of drugs I: development of in situ vaginal drug absorption procedure. J Pharm Sci. 1975; 64(1):71-6. DOI: 10.1002/jps.2600640113. View

Joshi S, Dutta S, Kumar B, Katti U, Kulkarni S, Risbud A . Expanded safety study of Praneem polyherbal vaginal tablet among HIV-uninfected women in Pune, India: a phase II clinical trial report. Sex Transm Infect. 2008; 84(5):343-7. DOI: 10.1136/sti.2007.029207. View

Bentley M, Morrow K, Fullem A, Chesney M, Horton S, Rosenberg Z . Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect. 2000; 32(4):184-8. View

10.

Braunstein S, van de Wijgert J . Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt). 2005; 14(5):424-33. DOI: 10.1089/jwh.2005.14.424. View

11.

Dezzutti C, Guenthner P, Cummins Jr J, Cabrera T, Marshall J, Dillberger A . Cervical and prostate primary epithelial cells are not productively infected but sequester human immunodeficiency virus type 1. J Infect Dis. 2001; 183(8):1204-13. DOI: 10.1086/319676. View

12.

Jespers V, Van Roey J, Beets G, Buve A . Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr. 2006; 44(2):154-8. DOI: 10.1097/QAI.0b013e31802bb35f. View

13.

Joglekar N, Joshi S, Navlakha S, Katti U, Mehendale S . Acceptability of Praneem polyherbal vaginal tablet among HIV uninfected women & their male partners in Pune, India--Phase I study. Indian J Med Res. 2006; 123(4):547-52. View

14.

Hwu J, Tseng W, Gnabre J, Giza P, Huang R . Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J Med Chem. 1998; 41(16):2994-3000. DOI: 10.1021/jm970819w. View

15.

Mayer K, Karim S, Kelly C, Maslankowski L, Rees H, Profy A . Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS. 2003; 17(3):321-9. DOI: 10.1097/00002030-200302140-00005. View

16.

Pudney J, Quayle A, Anderson D . Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod. 2005; 73(6):1253-63. DOI: 10.1095/biolreprod.105.043133. View

17.

Patterson B, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D . Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol. 1998; 153(2):481-90. PMC: 1852974. DOI: 10.1016/S0002-9440(10)65591-5. View

18.

Romano J, Malcolm R, Garg S, Rohan L, Kaptur P . Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS. 2009; 3(5):558-66. DOI: 10.1097/COH.0b013e328305b96e. View

19.

SCHUMACHER G . Biochemistry of cervical mucus. Fertil Steril. 1970; 21(10):697-705. View

20.

Dinge A, Nagarsenker M . Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS PharmSciTech. 2008; 9(2):349-56. PMC: 2976960. DOI: 10.1208/s12249-008-9047-7. View